Literature DB >> 9713595

Improved diagnosis of reactivated toxoplasmosis.

D Ashburn1, M M Davidson, A W Joss, T H Pennington, D O Ho-Yen.   

Abstract

AIMS: To identify antigens detected by western blotting in primary Toxoplasma gondii infection and determine their role in diagnosis of reactivated toxoplasmosis.
METHODS: Twenty three immunocompromised patients were tested by IgG western blotting. Patients were grouped retrospectively. Group 1 comprised 15 human immunodeficiency (HIV)/AIDS patients and included: group 1A (six patients with clinical and/or serological evidence of reactivation), group 1B (five patients with clinical evidence only), and group 1C (four asymptomatic patients). Group 2 comprised eight non-HIV/AIDS immunocompromised patients with clinical and/or serological evidence of reactivation. Immunocompetent patients (n = 23) with primary toxoplasmosis were a control group used to determine the progression of the antigens detected.
RESULTS: In primary toxoplasmosis, antibodies against 6, 20, 22, 23, 25, 28, 29, and 36 kDa antigens predominated. Detection of four or more of the 6, 20, 22, 23, 25, and 36 kDa antigens was considered to be western blot positive. In two group 1A patients, western blotting indicated past infection. During reactivation, this reverted to being western blot positive. Three other group 1A patients were western blot positive. In three of five group 1B patients, western blot positive results improved serological diagnosis of reactivated toxoplasmosis (p < 0.05). In two of five group 1B patients and all four group 1C patients, western blot indicated past infection. In group 2, two of eight patients reverted from a pattern of past infection to western blot positive. Five other patients from group 2 were western blot positive.
CONCLUSIONS: Detection of some low molecular weight antigens is diagnostic of reactivated toxoplasmosis. These antigens can be detected even with normal dye test titres and their detection improves the diagnosis of reactivated toxoplasmosis. They might be the result of the release of bradyzoites from ruptured tissue cysts.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713595      PMCID: PMC395619          DOI: 10.1136/mp.51.2.105

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  23 in total

1.  Western blot analysis of the antibody response of patients with AIDS and toxoplasma encephalitis: antigenic diversity among Toxoplasma strains.

Authors:  L M Weiss; S A Udem; H Tanowitz; M Wittner
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  The infection-stage-related IgG response to Toxoplasma gondii studied by immunoblotting.

Authors:  C Verhofstede; P Van Gelder; M Rabaey
Journal:  Parasitol Res       Date:  1988       Impact factor: 2.289

Review 4.  Toxoplasmic encephalitis in patients with AIDS.

Authors:  D M Israelski; J S Remington
Journal:  Infect Dis Clin North Am       Date:  1988-06       Impact factor: 5.982

5.  Congenital toxoplasmosis: a prospective survey in the West of Scotland.

Authors:  K A Williams; J M Scott; D E Macfarlane; J M Williamson; T F Elias-Jones; H Williams
Journal:  J Infect       Date:  1981-09       Impact factor: 6.072

6.  High predictive value of Toxoplasma gondii IgG antibody levels in HIV-infected patients for diagnosis of cerebral toxoplasmosis.

Authors:  C Hellerbrand; F D Goebel; R Disko
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-11       Impact factor: 3.267

7.  Analysis of Toxoplasma gondii antigens recognized by human sera obtained before and after acute infection.

Authors:  I Potasman; F G Araujo; G Desmonts; J S Remington
Journal:  J Infect Dis       Date:  1986-10       Impact factor: 5.226

8.  Identification of an antigen-specific immunoglobulin M antibody associated with acute Toxoplasma infection.

Authors:  H A Erlich; G Rodgers; P Vaillancourt; F G Araujo; J S Remington
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

9.  Western Blot analysis of the antigens of Toxoplasma gondii recognized by human IgM and IgG antibodies.

Authors:  S D Sharma; J Mullenax; F G Araujo; H A Erlich; J S Remington
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

10.  Circulating antigen of Toxoplasma gondii in patients with AIDS: significance of detection and structural properties.

Authors:  A Hassl; H Aspöck; H Flamm
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1988-11
View more
  6 in total

1.  Immunoblot profile as predictor of toxoplasmic encephalitis in patients infected with human immunodeficiency virus.

Authors:  C Leport; J Franck; G Chene; F Derouin; J L Ecobichon; S Pueyo; J M Miro; B J Luft; P Morlat; H Dumon
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  Immunoblotting can help the diagnosis of ocular toxoplasmosis.

Authors:  D O Ho-Yen; D J Chapman; D Ashburn
Journal:  Mol Pathol       Date:  2000-06

3.  Specific, sensitive, and rapid diagnosis of active toxoplasmosis by a loop-mediated isothermal amplification method using blood samples from patients.

Authors:  Yee Ling Lau; Puviarasi Meganathan; Parthasarathy Sonaimuthu; Girija Thiruvengadam; Veeranoot Nissapatorn; Yeng Chen
Journal:  J Clin Microbiol       Date:  2010-07-21       Impact factor: 5.948

4.  Unspecific reactivity of IgM directed against the low-molecular-weight antigen of Toxoplasma gondii.

Authors:  A Dao; N Azzouz; C Eloundou Nga; J F Dubremetz; R T Schwarz; B Fortier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-24       Impact factor: 3.267

5.  Toxoplasmosis as a rare cause of symptomatic cervical lymphadenopathy.

Authors:  U S Kale; J Carlin
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2000-07

6.  Improvement and Evaluation of Loop-Mediated Isothermal Amplification for Rapid Detection of Toxoplasma gondii Infection in Human Blood Samples.

Authors:  Xi-Meng Sun; Yong-Sheng Ji; Xian-Yong Liu; Mei Xiang; Guang He; Li Xie; Jing-Xia Suo; Xun Suo
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.